Menu
Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Issue 1
Clinical Pharmacology: Advances and Applications
ISSN: 1179-1438
- View all (269)
- Volume 16, 2024 (2)
- Volume 15, 2023 (12)
- Volume 14, 2022 (12)
- Volume 13, 2021 (27)
- Volume 12, 2020 (28)
- Volume 11, 2019 (16)
- Volume 10, 2018 (19)
- Volume 9, 2017 (19)
- Volume 8, 2016 (20)
- Volume 7, 2015 (14)
- Volume 6, 2014 (23)
- Volume 5, 2013 (30)
- Volume 4, 2012 (11)
- Volume 3, 2011 (7)
- Volume 2, 2010 (28)
- Volume 1, 2009 (1)
Archive: Volume 5, 2013
- Issue 1 (23)
- Supplement 1 (7)
Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum
Decker BS, O’Neill KD, Chambers MA, Slaven JE, Yu Z, Jones DR, Moe SM
Clinical Pharmacology: Advances and Applications 2013, 5:193-199
Published Date: 10 December 2013
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang CW, Kovacs RJ, Flockhart DA
Clinical Pharmacology: Advances and Applications 2013, 5:185-192
Published Date: 9 December 2013
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Clinical Pharmacology: Advances and Applications 2013, 5:177-184
Published Date: 6 December 2013
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Lozano R, Domeque N, Apesteguia AF
Clinical Pharmacology: Advances and Applications 2013, 5:175-176
Published Date: 22 November 2013
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes
Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G
Clinical Pharmacology: Advances and Applications 2013, 5:167-174
Published Date: 19 November 2013
High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
Yabuno K, Seki M, Miyawaki K, Miwa Y, Tomono K
Clinical Pharmacology: Advances and Applications 2013, 5:161-166
Published Date: 5 November 2013
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
Lozano R, Domeque N, Apesteguia AF
Clinical Pharmacology: Advances and Applications 2013, 5:153-159
Published Date: 27 September 2013
Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation
Pickett A
Clinical Pharmacology: Advances and Applications 2013, 5:149-152
Published Date: 5 September 2013
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban
Kwong LM
Clinical Pharmacology: Advances and Applications 2013, 5:143-148
Published Date: 2 August 2013
Single-dose fentanyl sublingual spray for breakthrough cancer pain
Taylor DR
Clinical Pharmacology: Advances and Applications 2013, 5:131-141
Published Date: 24 July 2013
Impact of denosumab on bone mass in cancer patients
Brown-Glaberman U, Stopeck AT
Clinical Pharmacology: Advances and Applications 2013, 5:117-129
Published Date: 4 July 2013
Synthetic cathinone abuse
Capriola M
Clinical Pharmacology: Advances and Applications 2013, 5:109-115
Published Date: 2 July 2013
Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review
Brennan JL, Leung JG, Gagliardi JP, Rivelli SK, Muzyk AJ
Clinical Pharmacology: Advances and Applications 2013, 5:99-107
Published Date: 3 July 2013
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP
Clinical Pharmacology: Advances and Applications 2013, 5:85-97
Published Date: 10 June 2013
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Davis EM, Knezevich JT, Teply RM
Clinical Pharmacology: Advances and Applications 2013, 5:67-83
Published Date: 19 April 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE
Clinical Pharmacology: Advances and Applications 2013, 5:59-66
Published Date: 16 April 2013
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
Bartosh NS, Tomlin T, Cable C, Halka K
Clinical Pharmacology: Advances and Applications 2013, 5:53-58
Published Date: 15 March 2013
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
Prager W
Clinical Pharmacology: Advances and Applications 2013, 5:39-52
Published Date: 12 March 2013
Effect of statin therapy on vaspin levels in type 2 diabetic patients
Al-Azzam SI, Alzoubi KH, Abu Abeeleh J, Mhaidat NM, Abu-Abeeleh M
Clinical Pharmacology: Advances and Applications 2013, 5:33-38
Published Date: 20 February 2013
A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
van Rossem K, Lowe JA
Clinical Pharmacology: Advances and Applications 2013, 5:23-31
Published Date: 30 January 2013
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K, Moss AC
Clinical Pharmacology: Advances and Applications 2013, 5:21-22
Published Date: 22 January 2013
Arginine deprivation therapy for malignant melanoma
Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB
Clinical Pharmacology: Advances and Applications 2013, 5:11-19
Published Date: 27 December 2012
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
Thomas RP, Recht L, Nagpal S
Clinical Pharmacology: Advances and Applications 2013, 5:1-9
Published Date: 27 December 2012